Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007;50(11):2239–44.
DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013;62(5):1405–8.
Frontoni S, Di Bartolo P, Avogaro A, Bosi E, Paolisso G, Ceriello A. Glucose variability: an emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract. 2013;102(2):86–95.
Kovatchev BP. Metrics for glycaemic control—from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol. 2017;13(7):425–36.
Bergenstal RM. Glycemic variability and diabetes complications: does it matter? simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615–21.
Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, Heatlie G, Loke Y, Rutter MK, Mamas MA. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–69.
Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes care. 2017;40(6):777–83.
Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care. 2008;31(11):2198–202.
Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011;13(9):921–8.
Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–40.
Borot S, Benhamou PY, Atlan C, Bismuth E, Bonnemaison E, Catargi B, Charpentier G, Farret A, Filhol N, Franc S, et al. Practical implementation, education and interpretation guidelines for continuous glucose monitoring: a French position statement. Diabetes Metab. 2018;44(1):61–72.
Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L. Improving the Clinical Value and Utility of CGM Systems: issues and Recommendations: A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care. 2017;40(12):1614–21.
Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19(9):644–55.
McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7(2):253–63.
Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8(5):342–8.
Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17(11):787–94.
Hoss U, Budiman ES. Factory-calibrated continuous glucose sensors: the science behind the technology. Diabetes Technol Ther. 2017;19:S44–50.
Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care. 1997;20(11):1655–8.
Fabris C, Patek SD, Breton MD. Are risk indices derived from CGM interchangeable with SMBG-based indices? J Diabetes Sci Technol. 2015;10(1):50–9.
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64.
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–603.
Sun B, He F, Gao Y, Zhou J, Sun L, Liu R, Xu H, Chen X, Zhou H, Liu Z, et al. Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes. Endocrine. 2019;64(3):536–43.
Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hamet P, Mancia G, Poulter N, Harrap S, Woodward M, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359–65.
Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, Perego C, Muscogiuri G. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev. 2011;7(5):313–24.
Bruginski D, Precoma DB, Sabbag A, Olandowski M. Impact of glycemic variability and hypoglycemia on the mortality and length of hospital stay among elderly patients in Brazil. Curr Diabetes Rev. 2020;16(2):171–80.
Slieker RC, van der Heijden A, Nijpels G, Elders PJM. Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort. Cardiovasc Diabetol. 2019;18(1):170.
Lu J, Ma X, Zhou J, Zhang L, Mo Y, Ying L, Lu W, Zhu W, Bao Y, Vigersky RA, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41(11):2370–6.
Picconi F, Parravano M, Ylli D, Pasqualetti P, Coluzzi S, Giordani I, Malandrucco I, Lauro D, Scarinci F, Giorno P, et al. Retinal neurodegeneration in patients with type 1 diabetes mellitus: the role of glycemic variability. Acta Diabetol. 2017;54(5):489–97.
Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61(1):48–57.
Nusca A, Tuccinardi D, Albano M, Cavallaro C, Ricottini E, Manfrini S, Pozzilli P, Di Sciascio G. Glycemic variability in the development of cardiovascular complications in diabetes. Diab Metab Res Rev. 2018;34(8):e3047.
Cardoso CRL, Leite NC, Moram CBM, Salles GF. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol. 2018;17(1):33.
Takahashi H, Iwahashi N, Kirigaya J, Kataoka S, Minamimoto Y, Gohbara M, Abe T, Okada K, Matsuzawa Y, Konishi M, et al. Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome. Cardiovasc Diabetol. 2018;17(1):116.
Xia J, Yin C. Glucose variability and coronary artery disease. Heart Lung Circ. 2019;28(4):553–9.
Liang S, Yin H, Wei C, Xie L, He H, Liu X. Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis. J Diab Metab Disord. 2017;16:45.
Besch G, Pili-Floury S, Morel C, Gilard M, Flicoteaux G, Mont L, Perrotti A, Meneveau N, Chocron S, Schiele F, et al. Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis. Cardiovasc Diabetol. 2019;18(1):27.
Benalia M, Zeller M, Mouhat B, Guenancia C, Yameogo V, Greco C, Yao H, Maza M, Verges B, Cottin Y. Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction. Diab Metab. 2019;45(5):446–52.
Ito T, Ichihashi T, Fujita H, Sugiura T, Yamamoto J, Kitada S, Nakasuka K, Kawada Y, Ohte N. The impact of intraday glucose variability on coronary artery spasm in patients with dysglycemia. Heart Vessels. 2019;34(8):1250–7.
Pu Z, Lai L, Yang X, Wang Y, Dong P, Wang D, Xie Y, Han Z. Acute glycemic variability on admission predicts the prognosis in hospitalized patients with coronary artery disease: a meta-analysis. Endocrine. 2020;67(3):526–34.
Foreman YD, Brouwers M, Berendschot T, van Dongen M, Eussen S, van Greevenbroek MMJ, Henry RMA, Houben A, van der Kallen CJH, Kroon AA, et al. The oral glucose tolerance test-derived incremental glucose peak is associated with greater arterial stiffness and maladaptive arterial remodeling: the Maastricht Study. Cardiovasc Diabetol. 2019;18(1):152.
Gerbaud E, Darier R, Montaudon M, Beauvieux MC, Coffin-Boutreux C, Coste P, Douard H, Ouattara A, Catargi B. Glycemic. Diabetes Care. 2019;42(4):674–81.
Wang A, Liu X, Xu J, Han X, Su Z, Chen S, Zhang N, Wu S, Wang Y, Wang Y. Visit-to-visit variability of fasting plasma glucose and the risk of cardiovascular disease and all-cause mortality in the general population. J Am Heart Assoc. 2017;6:12.
Zhou JJ, Schwenke DC, Bahn G, Reaven P. Glycemic variation and cardiovascular risk in the veterans affairs diabetes trial. Diabetes Care. 2018;41(10):2187–94.
Tang X, Zhong J, Zhang H, Luo Y, Liu X, Peng L, Zhang Y, Qian X, Jiang B, Liu J, et al. Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):50.
Bancks MP, Carson AP, Lewis CE, Gunderson EP, Reis JP, Schreiner PJ, Yano Y, Carnethon MR. Fasting glucose variability in young adulthood and incident diabetes, cardiovascular disease and all-cause mortality. Diabetologia. 2019;62(8):1366–74.
Yu JH, Han K, Park S, Lee DY, Nam GE, Seo JA, Kim SG, Baik SH, Park YG, Kim SM, et al. Effects of long-term glycemic variability on incident cardiovascular disease and mortality in subjects without diabetes: a nationwide population-based study. Medicine. 2019;98(29):e16317.
Takao T, Matsuyama Y, Suka M, Yanagisawa H, Iwamoto Y. The combined effect of visit-to-visit variability in HbA1c and systolic blood pressure on the incidence of cardiovascular events in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2015;3(1):e000129.
Mo Y, Zhou J, Ma X, Zhu W, Zhang L, Li J, Lu J, Hu C, Bao Y, Jia W. Haemoglobin A1c variability as an independent correlate of atherosclerosis and cardiovascular disease in Chinese type 2 diabetes. Diab Vasc Dis Res. 2018;15(5):402–8.
Gu J, Fan YQ, Zhang JF, Wang CQ. Association of hemoglobin A1c variability and the incidence of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and arterial hypertension. Hellenic J Cardiol. 2018;59(2):91–7.
Gu J, Pan JA, Fan YQ, Zhang HL, Zhang JF, Wang CQ. Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus. Cardiovasc Diabetol. 2018;17(1):96.
Yokota S, Tanaka H, Mochizuki Y, Soga F, Yamashita K, Tanaka Y, Shono A, Suzuki M, Sumimoto K, Mukai J, et al. Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus. Cardiovasc Diabetol. 2019;18(1):166.
Akaza M, Akaza I, Kanouchi T, Sasano T, Sumi Y, Yokota T. Nerve conduction study of the association between glycemic variability and diabetes neuropathy. Diabetol Metab Synd. 2018;10:69.
Pai YW, Lin CH, Lee IT, Chang MH. Variability of fasting plasma glucose and the risk of painful diabetic peripheral neuropathy in patients with type 2 diabetes. Diabetes Metab. 2018;44(2):129–34.
Yang CP, Li CI, Liu CS, Lin WY, Hwang KL, Yang SY, Li TC, Lin CC. Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM. Neurology. 2017;88(10):944–51.
Su JB, Zhao LH, Zhang XL, Cai HL, Huang HY, Xu F, Chen T, Wang XQ. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients. Cardiovasc Diabetol. 2018;17(1):47.
Rosa L, Zajdenverg L, Souto DL, Dantas JR, Pinto MVR, Salles G, Rodacki M. HbA1c variability and long-term glycemic control are linked to diabetic retinopathy and glomerular filtration rate in patients with type 1 diabetes and multiethnic background. J Diabetes Compl. 2019;33(9):610–5.
Lai YR, Chiu WC, Huang CC, Tsai NW, Wang HC, Lin WC, Cheng BC, Su YJ, Su CM, Hsiao SY, et al. HbA1C Variability is strongly associated with the severity of peripheral neuropathy in patients with type 2 diabetes. Front Neurosci. 2019;13:90.
Lai YR, Huang CC, Chiu WC, Liu RT, Tsai NW, Wang HC, Lin WC, Cheng BC, Su YJ, Su CM, et al. HbA1C variability is strongly associated with the severity of cardiovascular autonomic neuropathy in patients with type 2 diabetes after longer diabetes duration. Front Neurosci. 2019;13:458.
Schreur V, van Asten F, Ng H, Weeda J, Groenewoud JMM, Tack CJ, Hoyng CB, de Jong EK, Klaver CCW, Jeroen Klevering B. Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus. Acta Ophthalmol. 2018;96(5):459–64.
Zhao Q, Zhou F, Zhang Y, Zhou X, Ying C. Fasting plasma glucose variability levels and risk of adverse outcomes among patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2019;148:23–31.
Song KH, Jeong JS, Kim MK, Kwon HS, Baek KH, Ko SH, Ahn YB. Discordance in risk factors for the progression of diabetic retinopathy and diabetic nephropathy in patients with type 2 diabetes mellitus. J Diab Invest. 2019;10(3):745–52.
Ceriello A, De Cosmo S, Rossi MC, Lucisano G, Genovese S, Pontremoli R, Fioretto P, Giorda C, Pacilli A, Viazzi F, et al. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes Obes Metab. 2017;19(11):1570–8.
Lee CL, Chen CH, Wu MJ, Tsai SF. The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes. Ther Adv Chronic Dis. 2020;11:2040622319898370.
Viazzi F, Russo GT, Ceriello A, Fioretto P, Giorda C, De Cosmo S, Pontremoli R. Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals. J Nephrol. 2019;32(4):517–25.
Lee MY, Huang JC, Chen SC, Chiou HC, Wu PY. Association of HbA1C variability and renal progression in patients with type 2 diabetes with chronic kidney disease stages 3(-)4. Int J Mol Sci. 2018;19:12.
Rama Chandran S, Tay WL, Lye WK, Lim LL, Ratnasingam J, Tan ATB, Gardner DSL. Beyond HbA1c: comparing glycemic variability and glycemic indices in predicting hypoglycemia in type 1 and type 2 diabetes. Diab Technol Ther. 2018;20(5):353–62.
Gomez AM, Munoz OM, Marin A, Fonseca MC, Rondon M, Robledo Gomez MA, Sanko A, Lujan D, Garcia-Jaramillo M, Leon Vargas FM. Different indexes of glycemic variability as identifiers of patients with risk of hypoglycemia in type 2 diabetes mellitus. J Diabetes Sci Technol. 2018;12(5):1007–15.
Gomez AM, Henao DC, Imitola Madero A, Taboada LB, Cruz V, Robledo Gomez MA, Rondon M, Munoz-Velandia O, Garcia-Jaramillo M, Leon Vargas FM. Defining high glycemic variability in type 1 diabetes: comparison of multiple indexes to identify patients at risk of hypoglycemia. Diabetes Technol Ther. 2019;21(8):430–9.
DeVries JH, Bailey TS, Bhargava A, Gerety G, Gumprecht J, Heller S, Lane W, Wysham CH, Zinman B, Bak BA, et al. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: a post hoc analysis of the SWITCH Trials. Diabetes Obes Metab. 2019;21(3):622–30.
Klimontov VV, Myakina NE. Glucose variability indices predict the episodes of nocturnal hypoglycemia in elderly type 2 diabetic patients treated with insulin. Diabetes Metab Syndr. 2017;11(2):119–24.
Uemura F, Okada Y, Torimoto K, Tanaka Y. Relation between hypoglycemia and glycemic variability in type 2 diabetes patients with insulin therapy: a study based on continuous glucose monitoring. Diabetes Technol Ther. 2018;20(2):140–6.
Zhong VW, Juhaeri J, Cole SR, Shay CM, Gordon-Larsen P, Kontopantelis E, Mayer-Davis EJ. HbA1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: a nested case-control study. J Diabetes Complications. 2018;32(2):203–9.
Lanspa MJ, Dickerson J, Morris AH, Orme JF, Holmen J, Hirshberg EL. Coefficient of glucose variation is independently associated with mortality in critically ill patients receiving intravenous insulin. Crit Care (London, England). 2014;18(2):R86.
Timmons JG, Cunningham SG, Sainsbury CA, Jones GC. Inpatient glycemic variability and long-term mortality in hospitalized patients with type 2 diabetes. J Diabetes Complications. 2017;31(2):479–82.
Lee CL, Sheu WH, Lee IT, Lin SY, Liang WM, Wang JS, Li YF. Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes. Diabetes Metab. 2018;44(2):121–8.
Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Morano S, Nicolucci A, et al. Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(8):1885–93.
Xu D, Fang H, Xu W, Yan Y, Liu Y, Yao B. Fasting plasma glucose variability and all-cause mortality among type 2 diabetes patients: a dynamic cohort study in Shanghai, China. Sci Rep. 2016;6:39633.
Echouffo-Tcheugui JB, Zhao S, Brock G, Matsouaka RA, Kline D, Joseph JJ. Visit-to-visit glycemic variability and risks of cardiovascular events and all-cause mortality: the ALLHAT Study. Diabetes Care. 2019;42(3):486–93.
Akirov A, Diker-Cohen T, Masri-Iraqi H, Shimon I. High glucose variability increases mortality risk in hospitalized patients. J Clin Endocrinol Metab. 2017;102(7):2230–41.
Walker GS, Cunningham SG, Sainsbury CAR, Jones GC. HbA1c variability is associated with increased mortality and earlier hospital admission in people with Type 1 diabetes. Diab Med. 2017;34(11):1541–5.
Critchley JA, Carey IM, Harris T, DeWilde S, Cook DG. Variability in glycated hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care cohort study. Diabetes Care. 2019;42(12):2237–46.
Sheng CS, Tian J, Miao Y, Cheng Y, Yang Y, Reaven PD, Bloomgarden ZT, Ning G. Prognostic significance of long-term HbA 1c variability for all-cause mortality in the ACCORD Trial. Diabetes Care. 2020;43(6):1185–90.
Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(6):476–86.
Ravona-Springer R, Heymann A, Schmeidler J, Moshier E, Guerrero-Berroa E, Soleimani L, Sano M, Leroith D, Preiss R, Tzukran R, et al. Hemoglobin A1c variability predicts symptoms of depression in elderly individuals with type 2 diabetes. Diabetes Care. 2017;40(9):1187–93.
Li TC, Yang CP, Tseng ST, Li CI, Liu CS, Lin WY, Hwang KL, Yang SY, Chiang JH, Lin CC. Visit-to-visit variations in fasting plasma glucose and HbA1c Associated With an Increased Risk of Alzheimer Disease: Taiwan Diabetes Study. Diabetes Care. 2017;40(9):1210–7.
Bancks MP, Carnethon MR, Jacobs DR Jr, Launer LJ, Reis JP, Schreiner PJ, Shah RV, Sidney S, Yaffe K, Yano Y, et al. Fasting glucose variability in young adulthood and cognitive function in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Diabetes Care. 2018;41(12):2579–85.
Saito Y, Noto H, Takahashi O, Kobayashi D. Visit-to-visit hemoglobin A1c variability is associated with later cancer development in patients with diabetes mellitus. Cancer J (Sudbury, Mass). 2019;25(4):237–40.
Breton MD, Patek SD, Lv D, Schertz E, Robic J, Pinnata J, Kollar L, Barnett C, Wakeman C, Oliveri M, et al. Continuous glucose monitoring and insulin informed advisory system with automated titration and dosing of insulin reduces glucose variability in type 1 diabetes mellitus. Diabetes Technol Ther. 2018;20(8):531–40.
Volcansek S, Lunder M, Janez A. Acceptability of continuous glucose monitoring in elderly diabetes patients using multiple daily insulin injections. Diabetes Technol Ther. 2019;21(10):566–74.
Avari P, Moscardo V, Jugnee N, Oliver N, Reddy M. Glycemic variability and hypoglycemic excursions with continuous glucose monitoring compared to intermittently scanned continuous glucose monitoring in adults with highest risk type 1 diabetes. J Diabetes Sci Technol. 2019. https://doi.org/10.1177/1932296819867688.
Deiss D, Szadkowska A, Gordon D, Mallipedhi A, Schutz-Fuhrmann I, Aguilera E, Ringsell C, De Block C, Irace C. Clinical practice recommendations on the routine use of eversense, the first long-term implantable continuous glucose monitoring system. Diabetes Technol Ther. 2019;21(5):254–64.
Iga R, Uchino H, Kanazawa K, Usui S, Miyagi M, Kumashiro N, Yoshino H, Ando Y, Hirose T. Glycemic variability in type 1 diabetes compared with Degludec and Glargine on the morning injection: an open-label randomized controlled trial. Diabetes Ther. 2017;8(4):783–92.
Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, Alba M. The Effect of Canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care. 2017;40(2):171–80.
Mathieu C, Dandona P, Phillip M, Oron T, Lind M, Hansen L, Thoren F, Xu J, Langkilde AM. Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2. Diabetes Care. 2019;42(6):1081–7.
Henry RR, Strange P, Zhou R, Pettus J, Shi L, Zhuplatov SB, Mansfield T, Klein D, Katz A. Effects of dapagliflozin on 24-hour glycemic control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2018;20(11):715–24.
Nishimura R, Osonoi T, Koike Y, Miyata K, Shimasaki Y. A randomized pilot study of the effect of trelagliptin and alogliptin on glycemic variability in patients with type 2 diabetes. Adv Ther. 2019;36(11):3096–109.
Bajaj HS, Venn K, Ye C, Patrick A, Kalra S, Khandwala H, Aslam N, Twum-Barima D, Aronson R. Lowest glucose variability and hypoglycemia are observed with the combination of a GLP-1 receptor agonist and basal insulin (VARIATION Study). Diabetes Care. 2017;40(2):194–200.
Frias JP, Nakhle S, Ruggles JA, Zhuplatov S, Klein E, Zhou R, Strange P. Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19(1):40–8.
Umpierrez GE, O’Neal D, DiGenio A, Goldenberg R, Hernandez-Triana E, Lin J, Park CY, Renard E, Kovatchev B. Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1317–21.
Sofizadeh S, Imberg H, Olafsdottir AF, Ekelund M, Dahlqvist S, Hirsch I, Filipsson K, Ahren B, Sjoberg S, Tuomilehto J, et al. Effect of liraglutide on times in glycaemic ranges as assessed by CGM for type 2 diabetes patients treated with multiple daily insulin injections. Diabetes Ther. 2019;10(6):2115–30.
Park SE, Lee BW, Kim JH, Lee WJ, Cho JH, Jung CH, Lee SH, Suh S, Hur GC, Kim SH, et al. Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study). Diabetes Obes Metab. 2017;19(6):892–6.
Kim NH, Kim DL, Kim KJ, Kim NH, Choi KM, Baik SH, Kim SG. Effects of vildagliptin or pioglitazone on glycemic variability and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a 16-week, randomised, open label, Pilot Study. Endocrinol Metab (Seoul, Korea). 2017;32(2):241–7.
Kim G, Oh S, Jin SM, Hur KY, Kim JH, Lee MK. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2017;18(12):1179–86.
Famulla S, Pieber TR, Eilbracht J, Neubacher D, Soleymanlou N, Woerle HJ, Broedl UC, Kaspers S. Glucose exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 diabetes: continuous glucose monitoring data from a 4-week, randomized, Placebo-Controlled Trial (EASE-1). Diabetes Technol Ther. 2017;19(1):49–60.
Suzuki D, Yamada H, Yoshida M, Funazaki S, Amamoto M, Morimoto J, Hara K. Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: a retrospective, single-center, pilot study. J Diabetes Invest. 2020.
Zhang Y, Zhao Z, Wang S, Zhu W, Jiang Y, Sun S, Chen C, Wang K, Mu L, Cao J, et al. Intensive insulin therapy combined with metformin is associated with reduction in both glucose variability and nocturnal hypoglycaemia in patients with type 2 diabetes. Diabetes Metab Res Rev. 2017;33:7.
Mori Y, Ohta T, Yokoyama J, Utsunomiya K. Effects of low-carbohydrate/high-monounsaturated fatty acid liquid diets on diurnal glucose variability and insulin dose in type 2 diabetes patients on tube feeding who require insulin therapy. Diabetes Technol Ther. 2013;15(9):762–7.
Blaychfeld-Magnazi M, Reshef N, Zornitzki T, Madar Z, Knobler H. The effect of a low-carbohydrate high-fat diet and ethnicity on daily glucose profile in type 2 diabetes determined by continuous glucose monitoring. Eur J Nutr. 2019. https://doi.org/10.1007/s00394-019-02043-z.
Ranjan A, Schmidt S, Damm-Frydenberg C, Holst JJ, Madsbad S, Norgaard K. Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: a randomized open-label crossover trial. Diabetes Obes Metab. 2017;19(10):1479–84.
Ahola AJ, Forsblom C, Harjutsalo V, Groop PH. Dietary carbohydrate intake and cardio-metabolic risk factors in type 1 diabetes. Diabetes Res Clin Pract. 2019;155:107818.
Eiswirth M, Clark E, Diamond M. Low carbohydrate diet and improved glycaemic control in a patient with type one diabetes. Endocrinol Diabetes Metab Case Rep. 2018;2018:18.
Chang CR, Francois ME, Little JP. Restricting carbohydrates at breakfast is sufficient to reduce 24-hour exposure to postprandial hyperglycemia and improve glycemic variability. Am J Clin Nutr. 2019;109(5):1302–9.
Henry CJ, Kaur B, Quek RYC, Camps SG. A low glycaemic index diet incorporating isomaltulose is associated with lower glycaemic response and variability, and promotes fat oxidation in Asians. Nutrients. 2017;9:5.
Camps SG, Kaur B, Quek RYC, Henry CJ. Does the ingestion of a 24 hour low glycaemic index Asian mixed meal diet improve glycaemic response and promote fat oxidation? A controlled, randomized cross-over study. Nutr J. 2017;16(1):43.
Shukla AP, Dickison M, Coughlin N, Karan A, Mauer E, Truong W, Casper A, Emiliano AB, Kumar RB, Saunders KH, et al. The impact of food order on postprandial glycaemic excursions in prediabetes. Diabetes Obes Metab. 2019;21(2):377–81.
Trico D, Filice E, Trifiro S, Natali A. Manipulating the sequence of food ingestion improves glycemic control in type 2 diabetic patients under free-living conditions. Nutr Diabetes. 2016;6(8):e226.
Figueira FR, Umpierre D, Casali KR, Tetelbom PS, Henn NT, Ribeiro JP, Schaan BD. Aerobic and combined exercise sessions reduce glucose variability in type 2 diabetes: crossover randomized trial. PLoS ONE. 2013;8(3):e57733.
Farabi SS, Carley DW, Smith D, Quinn L. Impact of exercise on diurnal and nocturnal markers of glycaemic variability and oxidative stress in obese individuals with type 2 diabetes or impaired glucose tolerance. Diabetes Vasc Dis Res. 2015;12(5):381–5.
Schein A, Correa A, Casali KR, Schaan BD. Are glucose levels, glucose variability and autonomic control influenced by inspiratory muscle exercise in patients with type 2 diabetes? Study protocol for a randomized controlled trial. Trials. 2016;17:38.
Karstoft K, Clark MA, Jakobsen I, Muller IA, Pedersen BK, Solomon TP, Ried-Larsen M. The effects of 2 weeks of interval vs continuous walking training on glycaemic control and whole-body oxidative stress in individuals with type 2 diabetes: a controlled, randomised, crossover trial. Diabetologia. 2017;60(3):508–17.
Paing AC, McMillan KA, Kirk AF, Collier A, Hewitt A, Chastin SFM. Dose-response between frequency of interruption of sedentary time and fasting glucose, the dawn phenomenon and night-time glucose in Type 2 diabetes. Diabetic Med. 2019;36(3):376–82.
Rafiei H, Robinson E, Barry J, Jung ME, Little JP. Short-term exercise training reduces glycaemic variability and lowers circulating endothelial microparticles in overweight and obese women at elevated risk of type 2 diabetes. Eur J Sport Sci. 2019;19(8):1140–9.
Nygaard H, Ronnestad BR, Hammarstrom D, Holmboe-Ottesen G, Hostmark AT. Effects of exercise in the fasted and postprandial state on interstitial glucose in hyperglycemic individuals. J Sport Sci Med. 2017;16(2):254–63.
Figueira FR, Umpierre D, Bock PM, Waclawovsky G, Guerra AP, Donelli A, Andrades M, Casali KR, Schaan BD. Effect of exercise on glucose variability in healthy subjects: randomized crossover trial. Biol Sport. 2019;36(2):141–8.
Solomon TPJ, Tarry E, Hudson CO, Fitt AI, Laye MJ. Immediate post-breakfast physical activity improves interstitial postprandial glycemia: a comparison of different activity-meal timings. Pflugers Arch. 2020;472(2):271–80.
Martin CT, Criego AB, Carlson AL, Bergenstal RM. Advanced technology in the management of diabetes: which comes first-continuous glucose monitor or insulin pump? Curr DiabRep. 2019;19(8):50.
Kovatchev B, Cobelli C. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care. 2016;39(4):502–10.
Chico A, Aguilera E, Ampudia-Blasco FJ, Bellido V, Cardona-Hernandez R, Escalada FJ, Fernandez D, Gomez-Peralta F, Villar N, Gorgojo JJ, et al. Clinical approach to flash glucose monitoring: an expert recommendation. J Diabetes Sci Technol. 2020;14(1):155–64.
Gomez-Peralta F, Dunn T, Landuyt K, Xu Y, Merino-Torres JF. Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain. BMJ Open Diabetes Res Care. 2020;8:1.
Caprnda M, Mesarosova D, Ortega PF, Krahulec B, Egom E, Rodrigo L, Kruzliak P, Mozos I, Gaspar L. Glycemic variability and vascular complications in patients with type 2 diabetes mellitus. Folia Med. 2017;59(3):270–8.
Ohara M, Kohata Y, Nagaike H, Koshibu M, Gima H, Hiromura M, Yamamoto T, Mori Y, Hayashi T, Fukui T, et al. Association of glucose and blood pressure variability on oxidative stress in patients with type 2 diabetes mellitus and hypertension: a cross-sectional study. Diabetol Metab Syndr. 2019;11:29.
Rodrigues R, de Medeiros LA, Cunha LM, Garrote-Filho MDS, Bernardino Neto M, Jorge PT, Resende ES, Penha-Silva N. Correlations of the glycemic variability with oxidative stress and erythrocytes membrane stability in patients with type 1 diabetes under intensive treatment. Diabetes Res Clin Pract. 2018;144:153–60.